Cancer Antigen 125 Testing
Customize your policy alerts
Sign up for Anthem Policy CG-LAB-32 alerts
Get alerted when Policy CG-LAB-32 changes without checking for updates manually.
Monitor payer policy activity
This policy governs when quantitative CA-125 tumor-marker testing is medically necessary for evaluating suspected or diagnosed malignancy, assessing residual disease, monitoring treatment response, evaluating recurrence, and selected high-risk surveillance for Anthem commercial members.
A Summary for Members and Families section was added during the 08/13/2026 review.
The description, discussion/general information, references, and websites for additional information sections were revised during the 08/13/2026 review.
The Coding section was updated for 10/01/2026 ICD-10-CM changes and added codes QA1.790-QA1.791.
The 08/07/2025 review revised the description, discussion/general information, definitions, references, and websites for additional information sections.
The 08/08/2024 revision revised criteria for suspected ovarian cancer and repeat testing.
The 08/08/2024 revision added ICD-10-CM codes Z85.038, Z85.07, Z85.831, Z86.002 and removed C51.8.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.